leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Global Influenza Vaccines - World Industry Market Outlook 2017-2027

Global Influenza Vaccines - World Industry Market Outlook 2017-2027

Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other

Product code: PHA0160

  • Publication date: 03/01/2017
  • Number of Pages: 147
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $4.97 billion in 2017.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain’s new study tells you and tells you NOW.

In this brand new 147 page report you find 64 in-depth tables, charts and graphs – all unavailable elsewhere.

The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
Visiongain’s new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:
• Trivalent Influenza Vaccines (TIV)
• Quadrivalent Influenza Vaccines (QIV)

Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share
• Sanofi Pasteur
• GSK
• Seqirus
• AstraZeneca
• Protein Science Corporation.
• Others

From 2017, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations’ potentials.
Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses:
• Seasonal Influenza vaccines in development
• Universal Influenza vaccines in development

The report includes forecasts and analysis of pipeline developments for the following specific vaccines
• Fluzone / VaxiGrip
• Seqirus
• Fluarix / FluLaval
• FluMist / Fluenz
• FluBlok
• Other

The study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2027 for 11 countries:
• United States
• Japan
• The EU 5 - Germany, France, United Kingdom, Italy and Spain.
• Brazil, Russia, India and China.

Global Influenza Vaccines - World Industry Market Outlook 2017-2027

Who should read this report?
• Anyone within the influenza vaccines value chain.
• Pharmaceutical companies
• Vaccine manufacturers
• Healthcare biotech companies
• Generics and biosimilar producers
• Drug delivery companies and other technology providers
• Contract/clinical research organisations (CROs)
• Pharma contract manufacturers,
• Pharma/healthcare wholesale and distribution companies
• Medical device companies
• Healthcare diagnostics companies
• R&D specialists
• Business development managers
• Marketing managers
• Technologists
• Suppliers
• Investors
• Banks
• Government agencies
• Contractors

Visiongain’s study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.

Buy our report today Global Influenza Vaccines - World Industry Market Outlook 2017-2027: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other. Avoid missing out by staying informed – get our report now.

visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Report Overview
1.1 Global Influenza Vaccine Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to the World Influenza Vaccine Market
2.1 The Influenza Virus Kills over 500,000 People Every Year
2.2 Influenza has a Huge Social and Economic Burden on all Societies
2.3 The Influenza Virus Mutates Annually Rendering the Previous Year’s Vaccines Ineffective
2.3.1 All Current Influenza Vaccines are either Trivalent (TIV) or Quadrivalent (QIV)
2.3.2 The Antigenic Drift Mutation Causes Epidemics
2.3.3 The Antigenic Shift Mutation Causes Pandemics
2.4 An Epidemic or a Pandemic Outbreak?
2.4.1 Seasonal Influenza Epidemic (Local)
2.4.2 Pandemic Influenza (Worldwide): ‘A’ Subtype
2.4.3 Flu Vaccine Effectiveness
2.5 Key Influencers of the Influenza Vaccine Market
2.5.1 Governments and International Organisations
2.5.1.1 Every Year the World Health Organisation Identifies the Most Likely Strain of the Influenza Virus
2.5.1.2 The Governmental Stance of the Importance of Influenza Directly Drives the Market
2.5.1.3 The WHO’s “Influenza Vaccine Production Transfer Project” Affects Big Pharma’s Vaccine Sales
2.5.2 Leading Manufacturers
2.5.2.1 Sanofi Pasteur is the Market Leader
2.5.2.2 CSL Has Bought Novartis's Flu Vaccine Business Forming a New Infuenza Vaccine Company Seqirus
2.5.2.3 GSK is Now Third Placed in the Market
2.5.2.4 AstraZeneca’s Flumist Product is in Trouble

3. Influenza Vaccine World Market Outlook, 2017-2027
3.1 The World Influenza Market Performance, 2015
3.1.1 Growing Elderly Population
3.1.2 Paediatric Influenza Vaccines – High Demand Markets
3.1.3 Emerging Markets
3.2 The World Influenza Market Revenue Forecast for 2016-2027
3.3 The World Influenza Market: Industry Trends, 2017-2027
3.3.1 Demand Driven Trends
3.3.2 Supply Efficiency Affects Sales
3.3.3 Funding Trends
3.3.4 Protecting the Workforce of an Economy

4. TIV Vaccines will be Replaced by QIV Vaccines in the Near Future
4.1 Trivalent Influenza Vaccines (TIV)
4.2 Quadrivalent Vaccines (QIV)
4.3 Influenza Vaccines by TIV and QIV Type

5. Leading Influenza Vaccines: Revenue Predictions, 2017-2027
5.1 Sanofi Pasteur Influenza Vaccine Portfolio - Sales Forecasting and Discussion 2016-2027
5.2 Seqirus Vaccine Portfolio - Sales Forecasting and Discussion 2016-2027
5.3 GSK Influenza Vaccine Portfolio - Sales Forecasting and Discussion 2016-2027
5.4 AstraZeneca Influenza Vaccine - Sales Forecasting and Discussion 2016-2027
5.5 Protein Sciences Company Influenza Vaccine - Sales Forecasting and Discussion 2016-2027
5.6 Other Vaccines: Sales Forecasting and Discussion 2016-2027
5.7 Sanofi Pasteur Dominates the World Influenza Vaccines Market

6. Influenza Vaccines in Leading Developed Markets, 2017-2027
6.1 Influenza Vaccines: Leading Markets, 2015, 2021, 2027
6.1.1 Influenza Vaccine: Leading Developed Markets
6.2 The US Vaccine Market: 2017-2027
6.2.1 The US Vaccine Market: 2016
6.2.2 The US Vaccine Market Forecast: 2016-2027
6.2.3 Obama Healthcare Reform – the Benefits for Vaccine Sales
6.2.4 In the US Influenza Vaccines Come Equally from Manufacturers and Distributors
6.3 The Japanese Influenza Vaccine Market 2016-2027
6.3.1 The Japanese Vaccine Market 2016
6.3.2 The Japanese Vaccine Market Forecast 2016-2027
6.3.3 Filing the Vaccine Gap
6.3.4 Kaketsuken Loses Control of the Japanese Vaccine Market
6.4 The United Kingdom Influenza Vaccine Market 2017-2027
6.4.1 The UK Vaccine Market, 2016
6.4.2 The UK Vaccine Market, 2016-2027
6.4.3 Sanofi Pasteur’s QIV Vaccine is Authorized for use in the UK
6.5 The German Influenza Vaccine Market: 2017-2027
6.5.1 The German Vaccine Market, 2016
6.5.2 The German Vaccine Market: Forecast 2016-2027
6.6 The French Influenza Vaccine Market 2017-2027
6.6.1 The French Vaccine Market, 2016
6.6.2 The French Vaccine Market: Forecast 2016-2027
6.6.3 French Healthcare System – Events, Policies and Effects
6.6.4 The French Population Have the Highest Doubt over Vaccine Safety in Europe
6.7 The Italian Influenza Vaccine Market: 2017-2027
6.7.1 The Italian Vaccine Market: 2016
6.7.2 The Italian Vaccine Market Forecast: 2016-2027
6.7.3 Uncertain Foundation – Challenges in Public Healthcare
6.8 The Spanish Influenza Vaccine Market 2017-2027
6.8.1 The Spanish Vaccine Market: 2016
6.8.2 The Spanish Vaccine Market Forecast: 2016-2027
6.8.3 District Rules – Economic Challenges

7. Influenza Vaccines in Leading Emerging Markets, 2017-2027
7.1 Influenza Vaccines: Leading Markets, 2015, 2021, 2027
7.1.1 Influenza Vaccine: Leading Emerging National Markets
7.2 The Chinese Influenza Vaccine Market: 2017-2027
7.2.1 The Chinese Influenza Vaccine Market: 2016
7.2.2 The Chinese Influenza Vaccine Market Forecast: 2016-2027
7.2.3 High National Demand for Influenza Vaccines
7.3 The Indian Influenza Vaccine Market: 2017-2027
7.3.1 The Indian Vaccine Market: 2016
7.3.2 The Indian Influenza Vaccine Market Forecast: 2016-2027
7.3.3 Complications of Influenza Vaccines – How Much Progress Possible?
7.4 The Brazilian Influenza Vaccine Market: 2017-2027
7.4.1 The Brazilian Vaccine Market: 2016
7.4.2 The Brazilian Vaccine Market Forecast: 2016-2027
7.5 The Russian Vaccine Market: 2017-2027
7.5.1 The Russian Vaccine Market: 2016
7.5.2 The Russian Vaccine Market Forecast: 2016-2027
7.5.3 Power of the State

8. Research & Development Pipeline for Flu Vaccines
8.1 Seasonal Influenza Vaccines in Development
8.1.1 Sanofi Pasteur
8.1.1.1 Fluzone QIV High Dose
8.1.1.2 VaxiGrip QIV IM (6-35 months)
8.1.1.3 VaxiGrip QIV IM (3 years +)
8.1.2 Seqirus
8.1.2.1 MF59 QIV and TIV Vaccines
8.1.3 Takeda Pharmaceuticals
8.1.3.1 Takeda has Ceased Development of it’s TAK850 TIV Influenza Vaccine
8.1.4 Mitsubishi Tanabe Pharma
8.1.4.1 Plant Based Virus-Like- Particle Influenza Vaccine
8.2 Universal Influenza Vaccines in Development

9. Qualitative Analysis of the World Influenza Vaccines Industry and Market, 2017- 2027
9.1 SWOT Analysis of the World Influenza Vaccines Industry and Market, 2017
9.1.1 Strengths
9.1.1.1 Ageing Population
9.1.1.2 Influenza Prevention is Crucial
9.1.1.3 Sales Growth in Emerging National Markets
9.1.1.4 Rising Awareness of the Disease
9.1.2 Weaknesses
9.1.2.1 Supply Chain Costs
9.1.2.2 Time Pressure
9.1.2.3 Barriers to Market Entry
9.1.3 Opportunities
9.1.3.1 Strong Research and Development Pipeline
9.1.3.2 Vaccine Delivery – Innovations and Opportunities for Improvements
9.1.3.3 Universal Flu Vaccine
9.1.3.4 Adult Vaccines – High Need
9.1.4 Threats
9.1.4.1 Productivity Gap
9.2 STEP Analysis of the World Influenza Vaccines Industry and Market, 2017
9.2.1 Social Factors
9.2.1.1 Creating a Healthier Society
9.2.1.2 Public Fears of Side-Effects
9.2.2 Technological Forces
9.2.2.1 Advancements in Vaccine Technology
9.2.3 Economic Factors
9.2.3.1 Cost and Time Restraints
9.2.3.2 Emerging Markets Create Demand
9.2.4 Political Factors
9.2.4.1 Influence of Governments

10. Conclusion
10.1 Prevention of Influenza by Use of Flu Shots Rises in Importance
10.2 Japan as a Rising Consumer in the World Influenza Vaccine Market
10.3 Brazil and India Show Robust Growth
10.4 Emergence of a Universal Flu Vaccine
10.5 The US to Retain its Dominance
10.6 Concluding Remarks

List of Tables
Table 1.1 Selected National Vaccines Markets: Revenues ($m) and Market Shares (%) by Leading Country, 2017, 2021 and 2027
Table 2.1 Influenza Vaccine Effectiveness (%) 2004/5-2015/6
Table 3.1 Overall World Influenza Vaccine Market: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015- 2027
Table 3.2 The World Market for Influenza Vaccines Divided into that for Pharmaceutical Companies and ‘Others’; Revenue Forecast ($m) and Market Share (%), 2016- 2027
Table 4.1 Influenza Vaccines Divided into TIV and QIV Type, 2017
Table 5.1 Leading Influenza Vaccines: Revenues ($m), 2015
Table 5.2 Fluzone/VaxiGrip: Revenue ($m), 2013-2015
Table 5.3 Sanofi Pasteur (Fluzone/VaxiGrip); Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2027
Table 5.4 Seqirus Influenza Vaccines; Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2027
Table 5.5 Fluarix/FluLaval: Revenue ($m), 2013-2015
Table 5.6 Fluarix/FluLaval: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2027
Table 5.7 FluMist/Fluenz: Revenue ($m), 2013-2015
Table 5.8 FluMist/Fluenz: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2027
Table 5.9 FluBlok Revenue ($m), 2013-2014
Table 5.10 FluBlok: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2027
Table 5.11 Other Influenza Vaccines Forecast: ($m), Annual Growth ($m), CAGR (%), 2015-2027
Table 6.1 Influenza Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2015, 2021 and 2027
Table 6.2 The US Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2027
Table 6.3 The Japanese Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2026
Table 6.4 The UK Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 6.5 The German Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 6.6 The French Human Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 6.7 The Italian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 6.8 The Spanish Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 7.1 Human Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2015, 2021 and 2027
Table 7.2 The Chinese Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2027
Table 7.3 The Indian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 7.4 The Brazilian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 7.5 The Russian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 8.1 Seasonal Influenza Vaccines in Development, 2016
Table 8.2 Universal Influenza Vaccines in Development, 2016

List of Figures
Figure 1.1 Influenza Vaccines Market Segmentation
Figure 3.1 Influenza Vaccine’s Market Share of Global Vaccines Industry (%), 2015
Figure 3.2 Growth in the Uptake of Influenza Vaccines, 1990-2015
Figure 3.3 Influenza Vaccines: Segmentation by Age (%), 2015
Figure 3.4 Time of Last Influenza Vaccination by Age, 2016
Figure 3.5 Influenza Vaccines: Market Share by Geographical Region, 2015
Figure 3.6 The World Market for Influenza Vaccines Divided into Pharma Companies and ‘Others’, 2015- 2027
Figure 3.7 Influenza Market Share (%) by Pharma Companies and ‘Others’: 2015 and 2027
Figure 3.8 World Influenza Vaccines Market: Drivers and Restraints, 2017-2027
Figure 5.1 Fluzone/VaxiGrip: Revenue Forecast ($m), 2015-2027
Figure 5.2, Seqirus Influenza Vaccines; Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2027
Figure 5.3, GSK Influenza Vaccines; Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2027
Figure 5.4 FluMist/Fluenz: Revenue Forecast ($m), 2015-2027
Figure 5.5 FluBlok: Revenue Forecast ($m), 2015-2027
Figure 5.6 Other Influenza Vaccines: Revenue Forecast ($m), 2015-2027
Figure 5.7 Market Share (%) by Company of the Influenza Vaccine Market 2015 and 2027
Figure 5.8 Influenza Vaccines Market Revenues ($m) by Company, 2015-2027
Figure 6.1 Influenza Vaccine Market Share (%) by Country, 2015
Figure 6.2 Developed National Markets: Drivers and Restraints, 2016-2027
Figure 6.3 The US Influenza Vaccine Revenue Forecast ($m), 2016-2027
Figure 6.4 The Japanese Influenza Vaccine Revenue Forecast ($m), 2016-2027
Figure 6.5 The UK Influenza Vaccines Revenue Forecast ($m), 2016-2027
Figure 6.6 The German Influenza Vaccines Revenue Forecast ($m), 2016-2027
Figure 6.7 The French Influenza Vaccines Revenue Forecast ($m), 2016-2027
Figure 6.8 The Italian Influenza Vaccines Revenue Forecast ($m), 2016-2027
Figure 6.9 The Spanish Influenza Vaccines Revenue Forecast ($m), 2016-2027
Figure 7.1 Emerging National Markets: Drivers and Restraints, 2017-2027
Figure 7.2 The Chinese Influenza Vaccines Revenue Forecast ($m), 2016-2027
Figure 7.3 The Indian Influenza Vaccines Revenue Forecast ($m), 2016-2027
Figure 7.4 The Brazilian Influenza Vaccines Revenue Forecast ($m), 2016-2027
Figure 7.5 The Russian Influenza Vaccines Revenue Forecast ($m), 2016-2027
Figure 9.1 SWOT Analysis of the Influenza Vaccines Market, 2017
Figure 9.2 STEP Analysis of the Influenza Vaccines Market, 2017

Companies Listed

Advisory Committee for Immunization Practices
Astellas Pharmaceuticals
AstraZeneca
Bharat Immunologicals and Biologicals Corporation Limited
Binnopharm
bioCSL
BioManguinhos/Oswaldo Cruz Foundation
BiondVax
BiondVax
Bionor
Brazilian Ministry of Health
Butantan Institute
Center for Biologics Evaluation and Research
Centre for Disease Control and Prevention
China National Biotech Group
China’s National Regulatory Authority
Chinese Food and Drug Administration
CSL
CureVac
Daiichi Sankyo
Dynavax
Flanders Institute
Food and Drug Administration
FORT
Fresenius Pharmaceuticals
Gamma Vaccines
Gavi Alliance
Glaxo Smith Klein
GlaxoWellcome
Global Influenza Programme
Grippol
Health Service Bureau, Japan
Immune Targeting Systems
Indian Association of Paediatrics
Janssen Pharmaceuticals
Jenner Institute, University of oxford
Johnson & Johnson
Krka Pharmaceuticals
Medicago
Medicare
MedImmune
Merck
MSD Pharmaceuticals
National Health Service, UK
Novartis
Organisation for Economic Co-operation and Development
Panacea Biotech
Partnership for Influenza Vaccine Introduction
Petrovax
Pfizer
Protein Science Corporation
Sanofi Pasteur
Servizio Sanitario Nationale
Shionogi Pharmaceuticals
Sistema Unico de Saude
SmithKline Beecham
Takeda Pharmaceuticals
Terumo Pharmaceuticals
The Ministry of Health, Labour and Welfare, Japan
The Scripps Research Institute
Ultriks
US Department of Health and Human Services
VaxInnate
WHO Strategic Advisory Group of Experts
World Health Organization

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close